Fig. 2

DNA vaccination with HSP90 protects NZB/W mice from lupus disease manifestations. a Delayed development of proteinuria in NZB/W lupus mice that had been DNA-vaccinated with HSP90 as compared to HSP60 and controls (n = 10 per group). Monitoring occurred at the time points indicated on the x-axis. P < 0.002 in the comparison between PBS vs. pHSP90 and pcDNA3 vs. pHSP90. b Indirect immunofluorescence (IIF) for IgG deposition and hematoxylin/eosin (H/E) staining of renal glomeruli from NZB/W mice that had been DNA-vaccinated with control pcDNA3 or pHSP60 or pHSP90 22 weeks earlier. The graphs show the glomerular activity score (G.A.S.) and tubulointerstitial activity score (T.I.A.S.) measured in a blinded fashion from 6 fields (n = 6 mice per group). *P < 0.03 in the comparison between pcDNA3- and pHSP90-treated mice; **P < 0.05 in the comparison between pHSP60- and pHSP90-treated mice; ***P < 0.001 in the comparison between pcDNA3- or pHSP60- and pHSP90-treated mice